Abstract
Intermediate uveitis is a major anatomic category of uveitis with predominantly vitreous inflammation [1]. Systemic illnesses such as sarcoidosis and multiple sclerosis may be present, and infections or neoplasia can masquerade as intermediate uveitis. The classic undifferentiated form is pars planitis, which is identified by characteristic exudates overlying the peripheral retina and pars plana without evidence of systemic disease. Retinal vasculitis and macular edema are common accompaniments of vitreous inflammation. There is a worldwide incidence, and all age groups and both genders are affected.
Patients with mild disease were often observed without treatment in the past. Both medical and surgical therapies are now employed for a wider range of disease. Medical therapies are standard ones used in the treatment of all uveitis, but surgical therapy with cryoretinopexy, panretinal photocoagulation, or vitrectomy is relatively specific for intermediate uveitis and may lead to remission in some cases. Control of cystoid macular edema is probably the most common factor in determining long-term visual outcome. Normal or near-normal vision is an attainable goal in almost all cases, but achieving this may require consultation with a subspecialist ophthalmologist experienced in the management of uveitis.